On Friday, Viggle Inc (NASDAQ:VGGL)’s shares declined -20.39% to $2.46.
Viggle Inc (VGGL) declared the pricing of its formerly declared underwritten public offering of 3,626,179 shares of its common stock at a public offering price of $2.50 per share, resulting in gross proceeds of about $9,065,447.
The offering is predictable to close on May 28, 2015, subject to the satisfaction of customary closing conditions. The company has also granted the underwriters a 45-day option to purchase up to 543,927 additional shares of common stock to cover over-allotments, if any.
Viggle Inc. operates as a mobile and Web-based entertainment marketing platform for media companies, brands, and consumers in the United States. It guides users towards various forms of media consumption with television enhancement, music discovery, entertainment content publishing, and distributed viewing reminders.
Otonomy Inc (NASDAQ:OTIC)’s shares dropped -19.94% to $24.86.
Otonomy Inc (OTIC) declared topline results from its Phase 2b trial evaluating OTO-104 in patients with unilateral Meniere’s disease. The primary endpoint of the trial was reduction in vertigo frequency during Month 3 following treatment contrast to a one month baseline period. In the topline analysis, OTO-104 demonstrated a 61% reduction from baseline in vertigo frequency in Month 3 vs. 43% for placebo with a p value of 0.067, which narrowly missed achieving statistical significance. In addition to Month 3, a similar positive trend was also observed during Month 2 following treatment.
OTO-104 was well tolerated in the study and no drug-related serious adverse events were observed. Persistent perforations of the tympanic membrane at the end of Month 4 were observed in 2.6% of patients treated with OTO-104 which is compriseent with the findings from the OTO-104 Phase 1b trial in addition to published results for trials utilizing intratympanic injection of steroid solutions.
Otonomy, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States and Canada. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which accomplished Phase III clinical trials to treat pediatric patients with middle ear effusion or fluid at the time of tympanostomy tube placement surgery.
At the end of Friday’s trade, Aeropostale Inc (NYSE:ARO)‘s shares dipped -15.58% to $2.19.
Aeropostale Inc (ARO) stated results for the first quarter of fiscal 2015, and offered guidance for the second quarter of fiscal 2015.
First Quarter Performance
For the first quarter of fiscal 2015, net sales reduced 20% to $318.6 million, from $395.9 million in the year ago period. Comparable sales, counting the e-commerce channel, for the first quarter reduced 11%, contrast to a decrease of 13% for the corresponding 13-week period ended May 3, 2014.
The Company stated a net loss for the first quarter of fiscal 2015 of $45.3 million, or $0.57 per diluted share, which comprised of:
- an after-tax charge of $2.3 million, or $0.03 per diluted share, resulting from store closing costs, partially offset by
- an after-tax benefit of $1.1 million, or $0.02 per diluted share, resulting from a retirement plan settlement adjustment.
Aéropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing.
Orion Energy Systems, Inc. (NYSEMKT:OESX), ended its Friday’s trading session with -12.89% loss, and closed at $2.23.
Orion Energy Systems, Inc. (OESX) declared financial results for its fiscal 2015 fourth quarter and year ended March 31, 2015, highlighted by higher revenues driven by accelerating LED sales and gross margin expansion.
Operating and Financial Highlights
- Total revenue for the fiscal 2015 fourth quarter was $19.4 million, an enhance of 53.9% contrast to $12.6 million in the preceding-year period.
- LED lighting product sales raised to $10.4 million in the fiscal 2015 fourth quarter from $1.3 million in the preceding year period, accounting for 53.6% of total sales and 60.8% of total lighting product revenues.
- As of March 31, 2015, Orion had a lighting backlog of $6.9 million in LED and high-intensity fluorescent (HIF) lighting orders, contrast to a lighting backlog of $7.1 million as of December 31, 2014.
- During the fourth quarter, the Company secured large sales commitments from Ford Motor Company, Cardinal Health, Cincinnati Zoo, Trinity Plastics, US Post Offices, VA Hospitals, and other hospitals and school districts.
- The Company raised its network of active buying key regional resellers to 102 at March 31, 2015, up from 30 at March 31, 2014.
Orion Energy Systems, Inc. designs, manufactures, and markets various light-emitting diode (LED) retrofit fixtures for the commercial and industrial, office, auto dealership, convenient store, retail, and agri-business markets. Its products comprise configurable LED systems for use in cold storage applications; warehouses; food service applications; exterior LED parking lot, parking garage, canopy, up-lighting, and wallpack retrofits; recessed LED down lights and task lighting; and various high intensity fluorescent lighting systems. The company’s products also comprise dynamic energy control systems, motion sensors, and the Apollo solar light pipe to maximize energy efficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
